Cytotoxicity, acute and sub-chronic toxicities of the fruit extract of Tetrapleura tetraptera (Schumm. & Thonn.) Taub. (Fabaceae).
Cytotoxicity
Fabaceae
Spice
Tetrapleura tetraptera
Toxicity
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
04 Jul 2022
04 Jul 2022
Historique:
received:
08
02
2022
accepted:
29
06
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
Tetrapleura tetraptera is a medicinal spice traditionally used to treat cancer, diabetes, and several other ailments. This study analyzed the cytotoxicity of the dichloromethane methanol extract of T. tetraptera fruits (TTF) and its constituents. The toxicity profile of the TTF extract was also evaluated in rats. The Cytotoxicity of this extract was evaluated using the resazurin reduction assay (RRA). Acute and sub-chronic toxicity studies were performed according to the protocol described by the Organisation for Economic Cooperation, and Development (OECD). Hematological, serum, and urine biochemical parameters, as well as histological sections of the liver and kidney, were also evaluated based on standard methods. The TTF extract, compound 5, and the reference drug doxorubicin were active in all 9 tested cancer cell lines. The recorded IC TTF and its most active compound (5) are found to be potential cytotoxic agents, meanwhile, TTF was safe when given a single oral dose of 5000 mg/kg. However, caution is necessary in case of prolonged oral administration due to potential alterations of renal function at high doses (> 1000 mg/kg).
Sections du résumé
BACKGROUND
BACKGROUND
Tetrapleura tetraptera is a medicinal spice traditionally used to treat cancer, diabetes, and several other ailments. This study analyzed the cytotoxicity of the dichloromethane methanol extract of T. tetraptera fruits (TTF) and its constituents. The toxicity profile of the TTF extract was also evaluated in rats.
METHODS
METHODS
The Cytotoxicity of this extract was evaluated using the resazurin reduction assay (RRA). Acute and sub-chronic toxicity studies were performed according to the protocol described by the Organisation for Economic Cooperation, and Development (OECD). Hematological, serum, and urine biochemical parameters, as well as histological sections of the liver and kidney, were also evaluated based on standard methods.
RESULTS
RESULTS
The TTF extract, compound 5, and the reference drug doxorubicin were active in all 9 tested cancer cell lines. The recorded IC
CONCLUSION
CONCLUSIONS
TTF and its most active compound (5) are found to be potential cytotoxic agents, meanwhile, TTF was safe when given a single oral dose of 5000 mg/kg. However, caution is necessary in case of prolonged oral administration due to potential alterations of renal function at high doses (> 1000 mg/kg).
Identifiants
pubmed: 35787267
doi: 10.1186/s12906-022-03659-1
pii: 10.1186/s12906-022-03659-1
pmc: PMC9252075
doi:
Substances chimiques
Plant Extracts
0
Doxorubicin
80168379AG
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
178Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2016 May 12;11(5):e0155334
pubmed: 27171151
Br J Cancer. 1996 Jul;74(2):194-9
pubmed: 8688321
Evid Based Complement Alternat Med. 2020 Oct 24;2020:6297475
pubmed: 33163083
Phytomedicine. 2016 Jul 15;23(8):856-63
pubmed: 27288921
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Med Res. 2009 Apr;1(1):8-12
pubmed: 22505958
Ann Oncol. 2010 Oct;21 Suppl 7:vii173-9
pubmed: 20943611
Eur J Biochem. 2000 Sep;267(17):5421-6
pubmed: 10951200
Phytomedicine. 2019 May;58:152853
pubmed: 30836216
J Ethnopharmacol. 2019 May 23;236:42-49
pubmed: 30771517
BMC Complement Med Ther. 2020 Sep 10;20(1):273
pubmed: 32912178
Chem Biol Interact. 2021 Jan 5;333:109334
pubmed: 33245930
Mol Med Rep. 2018 Jun;17(6):7757-7763
pubmed: 29620235
Evid Based Complement Alternat Med. 2021 Jul 19;2021:4051555
pubmed: 34335807
Biomed Res Int. 2015;2015:914813
pubmed: 25961047
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
J Natl Cancer Inst. 1977 Jul;59(1):221-6
pubmed: 327080
ScientificWorldJournal. 2018 Sep 10;2018:4020294
pubmed: 30275799
J Ethnopharmacol. 2021 Mar 1;267:113632
pubmed: 33253828
Asian Pac J Trop Med. 2012 Sep;5(9):686-91
pubmed: 22805718
BMC Res Notes. 2012 Jun 15;5:299
pubmed: 22709668
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
BMC Complement Altern Med. 2014 Jul 14;14:241
pubmed: 25023038
Phytomedicine. 2019 Jul;60:152832
pubmed: 31031043
Hum Exp Toxicol. 2001 Dec;20(12):625-30
pubmed: 11936576
Toxicol Rep. 2019 Jun 27;6:625-631
pubmed: 31367527
BMC Complement Altern Med. 2011 Nov 01;11:104
pubmed: 22044718
Heliyon. 2020 Nov 09;6(11):e05470
pubmed: 33225095
Front Pharmacol. 2021 Nov 08;12:732891
pubmed: 34819855
Phytomedicine. 2020 Apr 15;70:153215
pubmed: 32388040
Pan Afr Med J. 2016 May 16;24:66
pubmed: 27642406
Springerplus. 2013 Jul 31;2:363
pubmed: 23961425
Evid Based Complement Alternat Med. 2021 Jan 18;2021:8810368
pubmed: 34007300
Chem Biol Interact. 2020 Aug 1;326:109141
pubmed: 32454006
J Ethnopharmacol. 2011 Apr 12;134(3):803-12
pubmed: 21291988
Evid Based Complement Alternat Med. 2015;2015:423689
pubmed: 26356679
Phytomedicine. 2017 Sep 15;33:62-68
pubmed: 28887921
Biomed Res Int. 2021 Oct 18;2021:4259777
pubmed: 34708121
Nig Q J Hosp Med. 2011 Oct-Dec;21(4):299-302
pubmed: 23175895
Lipids Health Dis. 2015 May 24;14:50
pubmed: 26003803
J Ethnopharmacol. 2010 Aug 19;131(1):110-5
pubmed: 20561576
J Ethnopharmacol. 2012 Jul 13;142(2):374-82
pubmed: 22595661
Phytomedicine. 2020 Jun 8;76:153261
pubmed: 32559584
J Ethnopharmacol. 2021 Jul 15;275:114111
pubmed: 33848610
Front Pharmacol. 2017 Jun 02;8:343
pubmed: 28626426
Phytomedicine. 2014 Oct 15;21(12):1651-7
pubmed: 25442273